From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma

Journal of Experimental & Clinical Cancer Research

  ^{1    2    3    3} 

[1] 0000 0001 0379 7164, grid.216417.7, Department of Oncology, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China;0000 0001 0379 7164, grid.216417.7, Department of Oncology, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China;0000 0001 0379 7164, grid.216417.7, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China;0000 0001 0379 7164, grid.216417.7, Department of Oncology, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China;0000 0001 0379 7164, grid.216417.7, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China;

关键词: Hepatocellular carcinoma (HCC);    Immunotherapy;    Oncolytic virus;    Immune checkpoint blockade (ICB);    Adoptive cell transfer;   

DOI  :  10.1186/s13046-019-1396-4

来源: publisher

【 摘 要 】

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in HCC treatment, less than 40% of HCC patients are eligible for potentially curative therapies. Recently, cancer immunotherapy has emerged as one of the most promising approaches for cancer treatment. It has been proven therapeutically effective in many types of solid tumors, such as non-small cell lung cancer and melanoma. As an inflammation-associated tumor, it’s well-evidenced that the immunosuppressive microenvironment of HCC can promote immune tolerance and evasion by various mechanisms. Triggering more vigorous HCC-specific immune response represents a novel strategy for its management. Pre-clinical and clinical investigations have revealed that various immunotherapies might extend current options for needed HCC treatment. In this review, we provide the recent progress on HCC immunology from both basic and clinical perspectives, and discuss potential advances and challenges of immunotherapy in HCC.

【 授权许可】

CC BY